Resources

What makes a drug discovery consortium successful?

Supporting the race for treatments new collaboration launched to drive understanding of COVID-19

Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19.

Quantification of protein glycation using vibrational spectroscopy

Supporting the raceBritain’s biggest network of diagnostic labs are completed in 5 weeksfor treatments new collaboration launched to drive understanding of COVID-19

Sites in Milton Keynes, Glasgow and Alderley Park in Cheshire are now live and are already testing thousands of patient samples for coronavirus (COVID-19) each day.

Testing capacity increases as second Lighthouse Lab becomes fully operational

The second mega-lab at Alderley Park in Cheshire has begun to test thousands of patient samples a day for coronavirus.

Medicines Discovery Catapult, at Alderley Park, in partnership with industry and academia, advancing COVID-19 testing capacity

The Government announced the establishment of large scale national COVID-19 hub laboratories across the UK.

Guiding health researchers through the approvals needed to obtain NHS data

An introduction to the application of AI technology in the generation of insights from real-world health data sources

Boehringer Ingelheim Office Hours dedicated to Hearing Loss: supporting entrepreneurial research on hearing therapeutics

The Hearing Medicines Discovery Syndicate and Boehringer Ingelheim today announced a Boehringer Ingelheim Office Hours dedicated to Hearing Loss.

Medicines Discovery Catapult celebrate British Science Week by bringing junior and senior scientists together

To celebrate British Science Week, Medicines Discovery Catapult have brought their most experienced scientists together with their newest scientists to talk about their motivations to get into drug discovery, as well as the future of the field.